| T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial DW Lee, JN Kochenderfer, M Stetler-Stevenson, YK Cui, C Delbrook, ... The Lancet 385 (9967), 517-528, 2015 | 3128 | 2015 |
| CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy TJ Fry, NN Shah, RJ Orentas, M Stetler-Stevenson, CM Yuan, ... Nature medicine 24 (1), 20-28, 2018 | 1235 | 2018 |
| Mechanisms of resistance to CAR T cell therapy NN Shah, TJ Fry Nature reviews Clinical oncology 16 (6), 372-385, 2019 | 786 | 2019 |
| Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia W Haso, DW Lee, NN Shah, M Stetler-Stevenson, CM Yuan, IH Pastan, ... Blood, The Journal of the American Society of Hematology 121 (7), 1165-1174, 2013 | 664 | 2013 |
| CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial JY Spiegel, S Patel, L Muffly, NM Hossain, J Oak, JH Baird, MJ Frank, ... Nature medicine 27 (8), 1419-1431, 2021 | 335 | 2021 |
| CD4/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial NN Shah, SL Highfill, H Shalabi, B Yates, J Jin, PL Wolters, A Ombrello, ... Journal of Clinical Oncology 38 (17), 1938, 2020 | 325 | 2020 |
| Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell–depleted stem cell transplantation NN Shah, K Baird, CP Delbrook, TA Fleisher, ME Kohler, S Rampertaap, ... Blood, The Journal of the American Society of Hematology 125 (5), 784-792, 2015 | 236 | 2015 |
| Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22 H Qin, S Ramakrishna, S Nguyen, TJ Fountaine, A Ponduri, ... Molecular Therapy-Oncolytics 11, 127-137, 2018 | 232 | 2018 |
| Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL NN Shah, DW Lee, B Yates, CM Yuan, H Shalabi, S Martin, PL Wolters, ... Journal of Clinical Oncology 39 (15), 1650, 2021 | 220 | 2021 |
| Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia D Bhojwani, R Sposto, NN Shah, V Rodriguez, C Yuan, ... Leukemia 33 (4), 884-892, 2019 | 200 | 2019 |
| Treatment of intraocular retinoblastoma with vincristine and carboplatin C Rodriguez-Galindo, MW Wilson, BG Haik, TE Merchant, CA Billups, ... Journal of Clinical Oncology 21 (10), 2019-2025, 2003 | 199 | 2003 |
| Immunogenicity of CAR T cells in cancer therapy DL Wagner, E Fritsche, MA Pulsipher, N Ahmed, M Hamieh, M Hegde, ... Nature reviews Clinical oncology 18 (6), 379-393, 2021 | 164 | 2021 |
| Secondary solid cancer screening following hematopoietic cell transplantation Y Inamoto, NN Shah, BN Savani, BE Shaw, AA Abraham, IA Ahmed, ... Bone marrow transplantation 50 (8), 1013-1023, 2015 | 164 | 2015 |
| Characterization of CD22 expression in acute lymphoblastic leukemia NN Shah, MS Stevenson, CM Yuan, K Richards, C Delbrook, RJ Kreitman, ... Pediatric blood & cancer 62 (6), 964-969, 2015 | 163 | 2015 |
| Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion L Amini, SK Silbert, SL Maude, LJ Nastoupil, CA Ramos, RJ Brentjens, ... Nature Reviews Clinical Oncology 19 (5), 342-355, 2022 | 149 | 2022 |
| Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma H Shalabi, IL Kraft, HW Wang, CM Yuan, B Yates, C Delbrook, ... Haematologica 103 (5), e215, 2018 | 149 | 2018 |
| Modulation of target antigen density improves CAR T-cell functionality and persistence S Ramakrishna, SL Highfill, Z Walsh, SM Nguyen, H Lei, JF Shern, H Qin, ... Clinical Cancer Research 25 (17), 5329-5341, 2019 | 139 | 2019 |
| Long-term outcomes following CD19 CAR T cell therapy for B-ALL are superior in patients receiving a fludarabine/cyclophosphamide preparative regimen and post-CAR hematopoietic … DW Lee III, M Stetler-Stevenson, CM Yuan, NN Shah, C Delbrook, ... Blood 128 (22), 218, 2016 | 138 | 2016 |
| Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL RM Myers, A Taraseviciute, SM Steinberg, AJ Lamble, J Sheppard, ... Journal of Clinical Oncology 40 (9), 932, 2022 | 123 | 2022 |
| Clinical utilization of chimeric antigen receptor T cells in B cell acute lymphoblastic leukemia: an expert opinion from the European Society for Blood and Marrow … AJ Kansagra, NV Frey, M Bar, TW Laetsch, PA Carpenter, BN Savani, ... Biology of blood and marrow transplantation 25 (3), e76-e85, 2019 | 105 | 2019 |
